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Randomized controlled trials are the principal means of establishing the efficacy of drugs. However pre-marketing
trials are limited in size and duration and exclude high-risk populations. They have limited statistical power to
detect rare but potentially serious adverse events in real-world patients. We summarize the principal
methodological challenges in the reporting, analysis and interpretation of safety data in clinical trials using recent
examples from systematic reviews. These challenges include the lack of an evidentiary gold standard, the limited
statistical power of randomized controlled trials and resulting type 2 error, the lack of adequate ascertainment of
adverse events and limited generalizability of trials that exclude high risk patients. We discuss potential solutions to
these challenges. Evaluation of drug safety requires careful examination of data from heterogeneous sources. Meta-
analyses of drug safety should include appropriate statistical methods and assess the optimal information size to
avoid type 2 errors. They should evaluate outcome reporting biases and missing data to ensure reliable and
accurate interpretation of findings. Regulatory and academic partnerships should be fostered to provide an
independent and transparent evaluation of drug safety.Review
Background
Randomized controlled trials are primarily designed to
provide reliable information on the efficacy of interven-
tions [1]. They form the primary basis of regulatory ap-
proval for a drug in the US, which involves demonstrating
evidence of efficacy and safety in two well-conducted
studies. With rare exceptions, these are generally inter-
preted as statistically significant data from two rando-
mized clinical trials. Several advances have been made in
the approach to the conduct, analysis and interpretation
of data from randomized controlled trials on efficacy out-
comes [1].
Since trials are typically carried out to define thera-
peutic benefit for regulatory approval, safety receives less
attention [2]. The role of drug safety regulation is to
protect patients from rare, severe adverse reactions;
most efforts are directed at early detection and preven-
tion of serious events such as that seen with thalido-
mide. Post-marketing surveillance through spontaneous
adverse event reporting systems are the mainstay of drug* Correspondence: ssingh31@jhu.edu
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distribution, and reproduction in any mediumsafety evaluation. Methodological issues around the ana-
lysis of safety data from clinical trials have received less
attention.
Systematic reviews and meta-analyses of clinical trials
have recently raised concerns about an increase in the
risk of serious adverse cardiovascular outcomes asso-
ciated with varenicline [2-4], an increased risk of mortal-
ity associated with the tiotropium Respimat inhaler, and
adverse cardiovascular outcomes associated with inhaled
anticholinergics (including the ipratropium and tiotro-
pium inhaler) [5,6]. Similarly, increased risks of myocar-
dial infarction associated with rosiglitazone [7-9] and
congestive heart failure and fractures associated with the
thiazolidinediones (rosiglitazone and pioglitazone) in
clinical trials have resulted in regulatory warnings
[10,11]. These findings have been widely debated with
conflicting interpretation by the academic community,
regulators and industry sponsors [12-14]. Regulators
have emphasized the limitations to defining and measur-
ing adverse outcomes in randomized controlled trials
and have called for caution in drawing any robust con-
clusions [12]. The lack of access to individual participant
data, the heterogeneous nature of safety data, and the
statistical challenges of analyzing rare events make safety
data from such meta-analyses difficult to analyze andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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methodological challenges in the reporting, analysis and
interpretation of safety data in clinical trials. We discuss
potential solutions to these challenges.
Methodological challenges
There are several challenges to identifying reliable drug
safety signals in clinical trials.
Lack of an evidentiary gold standard
There is no universally acceptable gold standard for de-
termining whether a drug safety signal represents a true
risk versus a false-positive signal. While evidentiary stan-
dards for efficacy are well established by regulatory sta-
tutes, the evidentiary standards for ascertaining safety
are heterogeneous and encompass various data sources
and study designs. Under the FDA Amendment Act of
2007, the FDA may revise a drug label to include a
warning about a clinically significant hazard when “there
is reasonable evidence of a causal association with a
drug” [17]. However, what level of evidence constitutes
reasonable evidence for regulatory action is open to
interpretation.
In a recent review of regulatory actions by the FDA in
2009 [18], approximately two thirds of major regulatory
actions on drug safety, including boxed warnings, with-
drawals and contraindications, relied on spontaneous
case reports [19]. Safety data from meta-analyses of clin-
ical trials have resulted in some warnings, such as the
warning on the potential association between antide-
pressants and suicidality [20] and boxed warnings on the
risk of myocardial ischemic events with rosiglitazone [8].
Limited statistical power
The premarketing clinical trials required for approval
of a drug primarily guard against type 1 error. RCTs
are usually statistically underpowered to detect the spe-
cific harm either by recruitment of a low-risk popula-
tion or low intensity of ascertainment of events. The
lack of statistical significance should not be used as
proof of clinical safety in an underpowered clinical
trial. As an example, varenicline is an alpha 4 beta 2
agonist approved for short-term abstinence among
smokers based on small short-term placebo-controlled
trials of efficacy [3-5]. Despite the high prevalence of
psychiatric comorbidity and cardiovascular disease
among smokers, the development program for vareni-
cline largely excluded such patients [3]. Only one RCT
was conducted among patients with cardiovascular
disease. A meta-analysis of 14 double-blind placebo-
controlled randomized controlled trials reported a sta-
tistically significant increase in serious adverse cardiac
events with varenicline [3]. Another intensive post-
marketing cohort study also reported on the underlyingmechanisms by which this cardiovascular hazard is
mediated [5].
Similarly, the reliance on surrogate endpoints to fa-
cilitate earlier access to drugs for chronic diseases limits
the size and duration of trials in which efficacy can be
demonstrated or where risk might be detectable [21].
The efficacy of an antidiabetic drug on glycated
hemoglobin can be adequately demonstrated in premar-
keting placebo controlled trials of modest size and dur-
ation [22]. Recent regulatory requirements stipulate
that drugs approved for the treatment of type 2 diabetes
should not demonstrate a significant cardiovascular
hazard (major adverse cardiovascular events) in pre-
approval trials with an upper bound of confidence
interval of 1.8 [22]. There are no regulatory require-
ments that drugs approved for type 2 diabetes lower the
micro- or macrovascular complications of type 2 dia-
betes [21]. Although a reliable diagnostic and prognos-
tic surrogate, it is unclear whether glycated hemoglobin
is a reliable treatment surrogate for drug approval of
type 2 diabetes [21]. The linkage between glycated
hemoglobin reduction and improved microvascular out-
comes may be reasonable for metformin and sulfony-
lurea [23]. However, three large long-term trials have
failed to show a cardiovascular benefit of intensive gly-
cemic control [24-26], and one large trial reported an
increase in mortality with intensive glycemic control
[25].
Lack of adequate ascertainment and classification of
adverse events
The inconsistencies in adverse effects reported in clinical
trials can create challenges. Adverse events are recorded
as secondary outcomes in trials and are usually not pre-
specified. Misclassification of adverse events is possible,
particularly where the outcomes are collected through
spontaneous reports from trial participants rather than
systematic monitoring. As an example, several recent
systematic reviews have raised the possibility that the
use of inhaled corticosteroids in patients with chronic
obstructive pulmonary disease or thiazolidinediones
among patients with type 2 diabetes may increase the
risk of pneumonia [27-29]. Radiographic or microbiolo-
gic confirmation of pneumonia was not available. Pneu-
monia was not prespecified as an outcome of interest,
but ascertained as adverse events or serious adverse
events in these trials. Whether the risk of pneumonia
seen in clinical trials of inhaled corticosteroids [27,28]
represents a potential misclassification of a subset of
COPD exacerbations is unknown. Similarly, the mis-
classification of congestive heart failure known to be
associated with thiazolidinedione use may have resulted
in the higher rates of pneumonia reported with thiazoli-
dinediones in clinical trials [29].
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The lack of generalizability of certain RCTs needs to be
acknowledged. Study participants are often carefully
selected, and the trial may have been designed to evalu-
ate only one particular dose, so there is no information
on dose-responsiveness. Hence, it may be difficult to ex-
trapolate the safety data to wider populations who may
be taking different doses or formulations. As an ex-
ample, the apparent safety of omeprazole when used to-
gether in a trial with clopidogrel has been questioned
because of the proprietary formulation used [30].
In another example, a meta-analysis of 17 clinical trials
reported a statistically significant increased risk of MI,
stroke and CV death with inhaled anticholinergics (ipratro-
pium bromide and tiotropium bromide) [7]. Data from an-
other formulation of tiotropium bromide delivered via the
Respimat inhaler showed a statistically significant increased
risk of mortality [6]. Most of these deaths were cardiovas-
cular deaths. These cardiovascular deaths were concen-
trated among patients with pre-existing arrhythmias and
cardiovascular disease. There is biologic and clinical evi-
dence that the cardiovascular risk of inhaled anticholiner-
gics is particularly concentrated among patients with
chronic obstructive pulmonary disease who also have con-
comitant cardiovascular disease [31]. Although a subse-
quent trial reported an increased risk of angina and
arrhythmias [32], it reported no increased risk of myocar-
dial infarction and composite stroke [32]. However, the ex-
clusion of patients with cardiovascular disease limited the
generalizability of its safety findings.Methodological opportunities
The analysis of safety data from clinical trials offers unique
methodological opportunities. In the case of gastrointestinal
hemorrhage with aspirin, even when the causal link be-
tween the drug and adverse effect is already well recog-
nized, the data from relevant trials potentially allow greater
precision in estimating the risk of harm [33]. This is par-
ticularly important where the benefit:harm ratio is finely
poised or for drugs used in primary prevention where
otherwise healthy patients have to live with adverse effects
of treatment in the hope of avoiding some future event.Systematic assessment of different data sources
The adverse events vary from mild symptomatic events
with a high background incidence to rare life-threatening
conditions. The timing of the adverse effects in relation to
duration of intervention may vary from immediate hyper-
sensitivity reactions to long-term cancer risk many years
down the line. Each source of data, be it spontaneous
reporting or RCT, has its own strengths and limitations.
The strengths and limitations of various data sources in
assessing adverse effects are shown in Table 1.Appropriate data sources should be carefully consid-
ered and chosen depending on the adverse effect of
interest and the study question. A single study design is
unlikely to reliably measure all the different possible ad-
verse effects, and focusing on certain study designs may
prove more fruitful, depending on the background inci-
dence of the particular outcome and the timing in rela-
tion to the intervention [33-35].
A comprehensive evaluation of the safety profile of a
drug requires collecting and synthesizing data on a di-
verse range of adverse events [34,35]. The choice of ap-
propriate study design is important not only because of
differences in the nature of adverse effects, but also be-
cause the diversity and complexities of the safety ques-
tions can only be addressed through evaluating multiple
sources of data [35]. A meta-analysis should ideally be
preceded by the systematic review process where rigor-
ous searches and assessment of validity and heterogen-
eity are carried out on the relevant trials to build a more
complete data set rather than just considering single
trials in isolation.
The adverse effects data from trials do not systematic-
ally differ from other study designs [36]. A recent study
found that among 58 meta-analyses that provided com-
parative data on odds ratios from observational studies
and trials, 93% had overlapping 95% confidence intervals
[36]. There were no consistent differences between ad-
verse effects data from RCTs compared to those of ob-
servational studies, with minimal differences in risk
estimates from RCTs and symmetrical funnel plots.
Randomized controlled trials are suited for evaluating
outcomes that occur fairly close to initiation of therapy
and that have a relatively high baseline incidence even in
untreated populations, and they provide the absolute or
relative risk increase for a specific adverse event. The RCT
generally offers an unconfounded comparison between
groups of patients, where the only difference is the inter-
vention delivered. The process of randomization with ad-
equate allocation concealment guards against selection
biases. Although randomized treat assignment in clinical
trials reduces the possibility of confounding at baseline, it
is possible that confounding may arise later from differen-
tial dropouts, crossover or changes in therapy.
In patients with type 2 diabetes mellitus, observational
studies of cardiovascular harm with thiazolidinedione ther-
apy as compared to metformin are potentially confounded
by the clinical tendency to use metformin early on, while
reserving thiazolidinediones for patients with poorly con-
trolled diabetes. Thus, data from placebo-controlled RCTs
have been critical in the evaluation of heart failure and risk
of myocardial infarction with rosiglitazone [7-9]. In con-
trast, pioglitazone and rosiglitazone are second-line agents
for the treatment of type 2 diabetes. Observational studies
comparing the two thiazolidinediones are less susceptible
Table 1 Key features and limitations of different approaches to assessing adverse effects of healthcare interventions
Study design Key features Limitations
Spontaneous or voluntary
reporting systems, including
journal-published case reports
Captures very wide range of events No denominator or control group, difficult to quantify risk
Particularly useful for detecting signals of
rare (low background incidence in treated
population) and/or unexpected events (e.g.,
new unrecognized pathology)
Format and type of information differs substantially among
regulators and journals
Sophisticated statistical techniques have
been developed for signal detection
Clinical details may be incomplete, causality uncertain
Selective reporting or under-reporting of cases
Randomized clinical trials Randomization reduces possibility of
confounding at baseline
Rigid recruitment criteria may lead to exclusion of patients
who are at risk of adverse effects
Certain adverse effects can be prospectively
specified for detailed monitoring
Powered for detection of significant difference between
groups for beneficial effect, estimates for adverse effects
may lack precisions
Intervention is typically well defined
Non-randomized studies ‘Real-world’ use with more generalizable
data and longer follow-up
Monitoring for rare or unexpected events may be less
rigorous, and the trials may not be of sufficient duration
to detect long-term problems
Potentially able to specify and assess rare
events as primary outcomes in case
control designs
Non-randomized nature is susceptible to confounding
May be able to explore relationship
to dose, duration and patient susceptibility
factors
Drug exposures are often based on computerized records
rather than dispensing or actual use
Meta-analysis of
controlled observational
studies and/or trials
Pooled analysis has greater power to
detect significant differences, even with
rare events
Reliant on quality of primary data
Missing or unreported data on adverse events is a major
problem, as are the statistical techniques of pooling sparse
data
Susceptible to selective outcome reporting of primary studiesAims to summarize complete data set
and can evaluate consistency of findings
among studies Heterogeneity within the pooled analysis
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ent clinical reasons why prescribers would selectively chan-
nel patients to either rosiglitazone or pioglitazone [10].
The strength of RCTs lies in the potential to maintain
blinded conditions when assessing adverse effects. The
use of placebo reduces the tendency for bias in select-
ively reporting or diagnosing adverse events. Lack of
blinding is particularly relevant when considering sub-
jective symptoms where participants’ inclination to re-
port certain events may be swayed by anticipation of
adverse affects potentially associated with the drug.
Equally, physicians may have a greater tendency to in-
vestigate, diagnose and report specific adverse events
that they consider likely to be related to the particular
drug intervention.
Since the analytical strength of the RCT lies in the com-
parison between groups, these may not be the most ap-
propriate design for signal detection of rare, unexpected
effects or for directly unveiling susceptibility factors in
subgroups of participants. However, the availability of in-
dividual patient data may subsequently make this possible.Data from spontaneous reporting systems may be of par-
ticular interest for detecting signals for rare, unusual ad-
verse events, such as the risk of suicide with varenicline
[19]. However, they have their own limitations, including
the lack of an appropriate denominator [37]. In certain
instances even spontaneous reports may result in decisive
regulatory action [37]. After the approval of felbamate for
epilepsy, there were spontaneous reports of aplastic
anemia at rates several times than that of historical con-
trols. This resulted in its withdrawal from the market.
Statistical analysis
Attention to the intention-to-treat analysis of all rando-
mized participants is important. Conducting the ana-
lysis using time on treatment or based on the extent of
drug exposure may result in loss of the benefit of
randomization and creation of a confounded compari-
son. However, in the case of a non-inferiority open label
safety trial, the conduct of an ITT analysis may provide
false reassurance of safety. In the Rosiglitazone Evalu-
ated for Cardiac Outcomes in Dysglycemia (RECORD)
Singh and Loke Trials 2012, 13:138 Page 5 of 8
http://www.trialsjournal.com/content/13/1/138Trial, the ITT analysis did not demonstrate non-
inferiority on cardiovascular outcomes with rosiglita-
zone versus the comparator [38]. However, in non-
inferiority trials both ITT and on-treatment analyses
need to be examined before ruling out the presence of a
significant safety hazard [39].
The appropriate statistical analysis plan should also con-
sider the biological plausibility and latency of the adverse
effect. The evaluation of the possibility of an increased
cancer risk with drugs should consider the latency period
and avoid lumping together short-term trials (e.g. of less
than a few months duration, where no such risk can be
detected) with long-terms studies, which may lead to the
dilution of the cancer risk. However, too long a latency
period should be avoided because often the specific timing
of the hazard is unknown.
As an example, in the PROspective pioglitAzone Clinical
Trial In macroVascular Events (PROactive) trial, there were
20 reported bladder tumor cases: 14 in the pioglitazone
group (n=2,605) and 6 in controls (n=2,633) [40]. An ini-
tial assessment by the study investigators concluded that
11 tumors that occurred within 1 year of randomization
(eight pioglitazone, three placebos) could not plausibly be
related to treatment. If pioglitazone accentuates the risk of
bladder cancer in patients with type 2 diabetes, then 1 year
may be a reasonable time frame, and such cases of bladder
cancer should not be removed from the statistical analysis.
After removing one case of bladder tumor in the placebo
arm that was benign, there was a statistically significant
increased risk of bladder cancer with pioglitazone in the
PROactive trial: 0.54% (14/2,605) cases of bladder cancer
in the pioglitazone arm versus 0.19% (5/2,633) cases of
bladder cancer in the control arm, respectively (RR 2.83;
95% CI 1.02—7.85, P=0.040) [41]. Pioglitazone was known
to be associated with bladder cancer in animal studies prior
to regulatory approval [41]. Although future observational
studies have provided further confirmation on the strength
of evidence of this association, conclusive proof linking
pioglitazone to bladder cancer in clinical trials was readily
available in 2005, nearly half a decade before clinicians and
patients were warned of such risks.
Ascertainment of adverse events
New or unexpected adverse effects cannot be prespeci-
fied in trial protocols. Even if such adverse effects were
not primary or secondary outcomes, any substantial im-
balance in rates between intervention arms in a trial
should be evaluated. Any weaknesses in ascertainment
in a randomized, double-blinded trial that should affect
the intervention arms equally are likely to be non-
differential and bias estimates toward null. A consistent
increase in the risk of pneumonia reported as an adverse
event or a serious adverse event in clinical trials of
inhaled corticosteroids increases our confidence in thestrength of this association [27]. Potential misclassifica-
tion of heart failure associated with thiazolidinediones as
pneumonia was a concern in clinical trials of the thiazo-
lidinediones, which reported an increased risk of pneu-
monia. However, readjudication of heart failure in the
PROactive trial showed that the impact of such mis-
classification was likely minimal [29].
To avoid ascertainment biases, trial protocols should
pre-specify monitoring for prespecified adverse events
based on pharmacological mechanisms or data from earl-
ier studies. Following publication of initial case reports of
newly diagnosed congestive heart failure with thiazolidine-
diones, subsequent RCTs were able to report heart failure
events with much greater detail, including adjudication by
independent committees [26]. The true role of adjudica-
tion of safety events in clinical trials remains unclear [42].
The reliance only on adjudicated major events may further
reduce statistical power because of a lower number of ad-
verse events recorded. Thus, sensitivity analysis using both
adjudicated as well as all serious adverse events should be
considered [3]. However, if the trial was appropriately ran-
domized and blinded, the presence or absence of adjudica-
tion should not differentially affect the relative rates of
adverse events between comparator arms. Reviewers and
trialists should attempt to measure blinding failure and
blinding biases when possible.
Statistical modeling of rare events in meta-analysis
The exact choice of statistical methods to evaluate safety
data will depend on the individual context. There is gen-
eral consensus that safety data should be modeled on the
relative scale as absolute risk models are underpowered
and result in type 2 error. The assessment of statistical
heterogeneity is appropriate but of lesser concern when
dealing with rare but serious adverse events where the pri-
mary focus is on detecting a signal if it exists. The com-
monly employed tests for statistical heterogeneity, e.g.,
Cochran’s test, are relatively underpowered. The Peto odds
ratio (OR) method with 95% confidence intervals may
provide the best confidence interval coverage, and is more
powerful and relatively less biased than random effects
analysis when dealing with low event rates [15]. Sensitivity
analyses using alternative statistical approaches such as
the fixed Mantel-Haenzsel odds ratio can also explore the
influence on effect size of the reciprocal of the treatment
arm continuity correction or no continuity correction for
trials with zero events [3,16].
Overcoming outcome reporting and funding biases and
missing data
Outcome reporting bias has also been identified as a major
issue in the assessment of efficacy and safety data in
industry-sponsored trials [43]. Reviewers should attempt
to identify data from multiple sources including clinical
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such key safety information from published trials, as
demonstrated in the case of pioglitazone above. The avail-
ability of complete adverse effects reports from the spon-
sor’s register has enabled far more detailed analysis of
cardiovascular events with rosiglitazone than pioglitazone
[7]. While pharmaceutical support does not automatically
make an analysis unreliable, the potential biases of
industry-sponsored investigators providing proof of safety
deserve closer scrutiny. In the case of rosiglitazone, an
analysis revealed that the investigators position on the car-
diovascular risks of rosiglitazone was closely aligned with
their sources of pharmaceutical support [44].
Loss to follow-up, particularly in long-term trials, is a
problem, particularly where there are differential losses be-
tween intervention arms. The benefits of randomization
will be diminished if the patients who continue within a
particular intervention arm are different from those origin-
ally randomized, thus leading to potential confounding.
Equally, the presence of differential losses and the cessation
of adverse event monitoring in patients who have with-
drawn could lead to imbalances in the rates of adverse
effects between arms. Distinction should be made between
patients who have completely left the trial as opposed to
those who have stopped taking the trial drug but remain
available for follow-up of adverse events. This should be
built into the original submission for ethical approval, and
patients re-consented at the time of stopping trial treat-
ment. This does not eliminate the possibility of confound-
ing but reduces the problem of missing adverse effects data
for patients who have withdrawn. Trials need to collect
safety data on prematurely withdrawn participants, and
safety data from such participants should be included in
the analysis. It was only after the inclusion of mortality data
on prematurely censored participants that a statistically sig-
nificant increased risk of mortality with tiotropium Respi-
mat in patients with COPD was demonstrated in clinical
trials [6].
Interpretation of safety data from trials
One needs to carefully consider the limitations of the
sample size and duration of the intervention in the con-
text of the adverse effect where ‘no significant harm’ is
reported. Undue reliance on the thresholds of statistical
significance or the small magnitude of statistical effect
should be avoided. A mere 8% increase in the risk of dia-
betes with statin therapy has potential public health sig-
nificance, irrespective of the threshold of statistical
significance [45]. The width of the 95% confidence inter-
vals, including the upper bounds, provides better assess-
ment of a clinically significant hazard in the context of
the benefit.
The power of the meta-analysis depends on the num-
ber of events, not the number of trials. Underpoweredstatistical models that utilize the absolute risk scale or
prematurely censor participants who remain in the trial
may further reduce the power of a meta-analysis. Such
underpowered safety studies should be interpreted with
caution. A meta-analysis that provides proof of safety
should be accompanied by information on the optimal
information size [46]. Evaluating the upper bounds of
the 95% confidence intervals is important when the pur-
pose is to rule out a significant risk
Conclusions
Trials are usually powered to detect benefit and seldom
designed with adverse events as primary outcome. It is not
possible to design trials to evaluate unexpected or un-
known adverse effects that have yet to be linked to the
intervention. Clinical trials should include explicit pre-
specified monitoring of pharmacologically predictable ad-
verse events and ensure adequate follow-up of withdrawn
participants. Recent regulatory guidance from the FDA
has limited the reporting of adverse events in clinical trials
from sponsors to those that are unexpected and consid-
ered related to the drug [47]. It is unclear how isolated
investigators will determine the causal relationship be-
tween a drug and its adverse events. The expanding role
of electronic trials registers with detailed study results has
potential that can only be fully realized when sponsors
provide reliable, accurate and complete data [48].
Empirical work is needed to evaluate whether novel
approaches such as mechanism-based drug toxicity
prediction can complement safety data from clinical
trials and improve an assessment of drug safety [49].
Methodological research is needed to determine
whether network meta-analysis techniques can pro-
vide reliable and valid comparative evaluation of drug
safety [50]. The European Medicines Agency has re-
cently undertaken methodological work to enhance
the consistency and transparency of their risk-benefit
decision-making process [51]. Current proposals
emphasize the need to not just consider the magni-
tude and consequences of treatment effects, but also
to evaluate less tangible factors such as the level of
uncertainty and extent of risk tolerance. These devel-
opments are particularly relevant when considering
rare but serious adverse events where the clinical
trials may yield imprecise or even conflicting esti-
mates. Multi-criteria decision analytical techniques
that accurately capture quantitative inputs and quali-
tative values from various stakeholders for risk-benefit
tradeoffs and allow for quantitative analysis and mod-
eling uncertainty on a range of outcomes can improve
complex regulatory decisions about drug safety.
Conducting health outcome trials prior to approval
increases the evidence base on safety. Post-marketing
safety studies of adequate design become mandatory in
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prove a drug. Regulators should be provided with ad-
equate resources and expertise to conduct such safety
evaluations. Regulatory and academic partnerships
should be fostered to provide an independent and trans-
parent evaluation of drug safety. The increasing pressure
by the public to make all clinical trial results available
and heightened public awareness about emerging drug
safety issues ensure that analyses of safety data from
clinical trials will remain central to the discussion
around drug safety in the foreseeable future.
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